DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Dimethyltryptamine is an investigational drug.
There have been 13 clinical trials for Dimethyltryptamine. The most recent clinical trial was a Phase 1 trial, which was initiated on November 1st 2018.
The most common disease conditions in clinical trials are Depression, Depressive Disorder, Major, and Depressive Disorder. The leading clinical trial sponsors are Heffter Research Institute, Johns Hopkins University, and GH Research Limited.
There are one hundred and forty-two US patents protecting this investigational drug and eight hundred and fifty-eight international patents.
Recent Clinical Trials for Dimethyltryptamine
|SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients||Small Pharma Ltd||Phase 1/Phase 2|
|Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder||Johns Hopkins University||Phase 2|
|Effects of Dimethyltryptamine in Healthy Subjects||Matthias Liechti||Phase 1|
Top disease conditions for Dimethyltryptamine
Top clinical trial sponsors for Dimethyltryptamine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Dimethyltryptamine||Start Trial||Methods of improving behavioral therapies||Emory University (Atlanta, GA)||Start Trial|
|Dimethyltryptamine||Start Trial||Complex and structurally diverse compounds||The Board of Trustees of the University of Illinois (Urbana, IL)||Start Trial|
|Dimethyltryptamine||Start Trial||Factor XIa inhibitors||Merck Sharp & Dohme Corp. (Rahway, NJ)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Dimethyltryptamine||World Intellectual Property Organization (WIPO)||WO2013142873||2032-03-23||Start Trial|
|Dimethyltryptamine||European Patent Office||EP3134408||2034-04-22||Start Trial|
|Dimethyltryptamine||World Intellectual Property Organization (WIPO)||WO2015164308||2034-04-22||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|